← Back to Patent Explorer
US4558007A Expired / Lapsed US ⏱️ 0.0 years remaining

Process for detecting LDHk isozyme activity in human serum for use as a diagnostic aid and for monitoring response to cancer therapy

Assignee: Health Research Inc
•
Filing: 1983-06-17
•
Granted: 1985-12-10
•
Expires: 2003-06-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An improved assay procedure for quantitatively detecting LDHk isozyme in human serum is provided which utilizes previously known electrophoretic gel separation procedures combined with an improved staining method wherein the staining solution has a constant temperature of about 37 DEG C. and a pH of about 8.0, and is contacted with the gel matrix for at least 3 hours in the absence of oxygen and light. This improved assay procedure may be used as an adjunct to other procedures for diagnosing the presence of primary cancer, as a post-operative indicator of metastatic cancer and in monitoring the success of cancer therapy.

Inventors

  • 👤 Garth R. Anderson
  • 👤 Kenneth F. Manly
  • 👤 Arnold Mittelman

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 23:07
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/5758; G01N33/57585; C; C12; C12Q; C12Q1/00; C12Q1/26; C12Q1/32; G01N2333/00; G01N2333/90; G01N2333/902; G01N2333/904; G01N2800/00; G01N2800/52

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 83 words
In a known process for quantitatively detecting LDH k isozyme in human serum utilizing reverse polarity electrophoresis on an imidazole/borate buffered polyacrylamide gel matrix according to known techniques, followed by staining the gel matrix using standard nitroblue tetrazolium/phenazine methasulfate or an equivalent staining solution, the improvement comprising continuously contacting said gel matrix with said staining solution having a constant temperature between 30°-40° C. for at least 3 hours in the absence of both oxygen and light to provide a suitable stain reaction time.
Claim 2
Dependent Claim 83 words
In a known process for quantitatively detecting LDH k isozyme in human serum utilizing reverse polarity electrophoresis on an imidazole/borate buffered polyacrylamide gel matrix according to known techniques, followed by staining the gel matrix using standard nitroblue tetrazolium/phenazine methasulfate or an equivalent staining solution, the improvement comprising continuously contacting said gel matrix with said staining solution having a constant temperature between 30°-40° C. for at least 3 hours in the absence of both oxygen and light to provide a suitable stain reaction time.
Claim 3
Dependent Claim 16 words
The improved process according to claim 1 wherein said gel is submerged within the staining solution.
Claim 4
Dependent Claim 22 words
The improved process according to claim 2 wherein the pH of the staining solution is maintained between 7.8-9.0 during said reaction time.
Claim 5
Dependent Claim 24 words
The improved process according to claim 3 wherein the temperature of the staining solution is maintained at about 37° C. during said reaction time.
Claim 6
Dependent Claim 21 words
The improved process according to claim 4 wherein the pH of the staining solution is about 8.0 during said reaction time.
Claim 7
Dependent Claim 29 words
The improved process according to claim 5 wherein the staining solution used during said reaction time has a pH of about 8.0 and a temperature of about 37° C.
Claim 8
Dependent Claim 15 words
The improved process according to claim 6 wherein said reaction time is between 3-8 hours.
Claim 9
Dependent Claim 16 words
The improved process according to claim 7 wherein said reaction time is at least 4.5 hours.
Claim 10
Dependent Claim 17 words
The improved process according to claim 8 wherein said staining process is performed in a nitrogen environment.
Claim 11
Dependent Claim 67 words
A method for determining in a patient the presence or absence of cancer which comprises extracting from said patient a sample of blood, and measuring the quantitative relative activity level of LDH k isozyme present within the serum of said sample by the method of claim 1 and comparing said level to the level of LDH k measured in the serum of an individual free of cancer.
Claim 12
Dependent Claim 30 words
The method of claim 10 wherein the patient's level of LDH k is compared with a standard curve showing average nomal or base line levels of serum LDH k activity.
Claim 13
Dependent Claim 50 words
The method of claim 11 wherein the LDH k activity is determined in said patient's serum after the patient has undergone treatment for cancer and compared with the level of LDH k activity in the serum of an individual free of cancer to determine whether metastasis has occurred after therapy.
Claim 14
Dependent Claim 48 words
The method of claim 12 wherein the LDH k activity level is determined in said patient's serum after the patient has undergone treatment for cancer and compared with the level of LDH k activity in the serum of an individual free of cancer to monitor cancer treatment response.
Claim 15
Dependent Claim 36 words
A method using LDH k isozyme as a serum marker for detecting the presence of cancer in a patient wherein the serum level of the patient's LDH k is determined by the method of claim 1.
Claim 16
Dependent Claim 117 words
A diagnostic test kit for performing the method of claim 1 comprising: (a) a given quantity of a suitable electrophoresis matrix for use in electrophoretically separating LDH k isozyme; (b) A given quantity of a borate buffer having a concentration greater than or equal to 10mM borate ion for treating the serum prior to or simultaneously with electrophoresis; (c) a given amount of appropriate staining reagents for the colorimetric determination of LDH k ; (d) means for excluding light and oxygen from the testing environment; (e) a positive control comprising an aliquot of purified LDH k ; (f) directions for the performance of said method; and (g) a container for housing the materials present in steps (a)-(f).

References Cited (Backward Citations)

US4258131A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-12-09 1989-06-10 1989-12-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-12-09 1993-06-10 1993-12-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-12-09 1997-06-10 1997-12-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag